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Aim. To present an up-to-date algorithm incorporating recent advances regarding its diagnosis and treatment. Method.A
Medline/PubmedsearchwasperformedtoidentifyrelevantstudiespublishedinEnglishfrom1990until2008.Onlyclinicalstudies
were identiﬁed and were used as basis for the diagnostic algorithm. Results. The eligible literature provided only observational
evidence. The vast majority of neck nodes from occult primaries (>90%) represent SCC with a high incidence among middle
aged man. Smoking and alcohol abuse are important risk factors. Asiatic and North African patients with neck node metastases
are at risk of harbouring an occult nasopharyngeal carcinoma. The remainder are adenocarcinoma, undiﬀerentiated carcinoma,
melanoma, thyroid carcinoma and Merkel cell carcinoma. Fine needle aspiration cytology (FNAC) reaches sensitivity and
speciﬁcity percentages of 81% and 100%, respectively and plays an important role as the second diagnostic step after routine
ENT mirror and/or endoscopic examination. FDG-PET/CT has proven to be helpful in identifying occult primary carcinomas
of the head and neck, especially when applied as a guiding tool prior to panendoscopy, and may induce treatment related
clinical decisions in up to 60% of cases. Conclusion. Although reports on the diagnostic process oﬀer mainly descriptive studies,
current information seems suﬃcient to formulate a diagnostic algorithm to contribute to a more systematic diagnostic approach
preventing unnecessary steps.
1.Introduction
Patientswithasuspiciouslumpintheneckareregularlyseen.
The overwhelming amount of possible diseases linked to a
swelling in the neck makes it of utmost importance to follow
astrictprotocolforappropriatediagnosismaking.Ifnot,this
might lead to a considerable diagnostic delay [1].
Neck node metastases from an unknown primary site
(UPS) are part of the “Cancer of Unknown Primary” origin,
where the primary tumor may remain unknown for a
patient’s lifetime despite thorough diagnostic work-up [2].
This clinical entity may develop by complete involution of
the primary or by a genetic inﬂuence, favoring metastatic
growth over primary tumor growth [3]. Although approxi-
mately one third of metastases from UPS are found in lymph
nodes [4], the incidence of neck nodes from UPS makes up
only 1.7%–5.5% of all head and neck carcinomas in large
series [1, 5, 6]. Over 90% of neck metastases comprises
squamous cell carcinoma (SCC) [7] whereas adenocarci-
noma, undiﬀerentiated carcinoma, and other malignancies
(e.g., thyroid carcinoma, melanoma) are less common in the
Western world. Undiﬀerentiated carcinomas are more often2 International Journal of Surgical Oncology
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Figure 1: The6sublevels of theneck according toRobbins et al. [9]
(Figure printed with permission of the publisher Bohn Staﬂeu van
Loghum, Houten, the Netherlands).
seen in countries with a high prevalence of nasopharyngeal
carcinomas.
2. Method
The Medline/Pubmed database was searched by using neck
node, cervical adenopathy, unknown primary, occult pri-
mary, and metastasis as search terms to identify relevant
studies published in English from 1990 until 2008. Out of
226 selected papers 34 relevant papers were selected after
reviewing the abstracts by two experienced head and neck
surgeons, a nuclear physician and a radiotherapist. Only
clinical descriptive studies were identiﬁed. These and two
Dutch publications [1, 8] were used as basis for a diagnostic
algorithm. Recommendations made in this paper reach a
level IV evidence (expert opinion).
2.1. Initial Diagnostic Work-Up of a Suspicious Lump in the
Neck. A neoplastic nature should be considered ﬁrstly in
patients beyond the age of 40 years, particularly those with
a history of alcohol abuse and heavy smoking. Racial traits
are also important: masses in the upper neck levels of Asiatic,
North African, and Indian patients are often related to occult
carcinoma in the nasopharynx [10] and oropharynx/oral
cavity [11], respectively.
Node metastases can be found in every neck level
(Figure 1), with metastases from UPS most frequently found
in level II [1, 5, 12, 13]. Neck nodes from UPS present
bilaterally in 10% of cases [12, 14]. In general, nodes in levels
I–III are attributed to a presumable primary SCC located in
the mucosa of the upper aerodigestive tract [15–17], whereas
nodes in levels IV and Vb more often arise from proximal
esophageal and thyroid carcinomas, but can also originate
from distant organs in the body, often containing adeno-
or large cell undiﬀerentiated carcinoma (LCUC). Lymph
nodes with adenocarcinoma are frequently accompanied by
multiple metastatic sites, such as lung, liver, and bones as
part of the CUP syndrome [18, 19]. Lymph nodes in level IIb
and Va are more typical for nasopharyngeal cancer. Nodes
in the parotid area originate most often from skin cancer
and should be distinguished from primary parotid tumors
and level I metastases from primary submaxillary gland
carcinomas. Melanoma containing nodes may occur in every
level of the neck, often involving superﬁcial, nuchal, level V,
and parotid lymph nodes [20].
When a suspicious node has been found, accurate
examination of the upper aerodigestive tract mucosa by
mirror examination and/or ﬁber-optic or rigid endoscopy is
r e q u i r e d ,a sw e l la s( b i m a n u a l )p a l p a t i o no ft h eo r o p h a r y n x
and mouth. If this results in the detection of a primary
carcinoma,furtherspeciﬁcdiagnosticmeasurescanbetaken.
If no primary tumor is detected, the next diagnostic step is
the ﬁne needle aspiration cytology (FNAC) of the node by an
experienced cytologist or surgeon. If the lesion is more dif-
ﬁcult to approach or cytology is nondiagnostic, ultrasound-
guided ﬁne needle aspiration cytology (USFNAC) has to be
performed.
2.2. Evaluation of Histopathological Characteristics. Neck
metastasespresentmostlyasﬁrm,solidmasses,butadistinct
subsetofmetastaticnodes present ascysticmassesfrequently
related to thyroid carcinoma followed by SCC and malignant
melanoma [21]. Goldenberg et al. [22] observed that certain
SCCs of the tonsil are more likely to produce cystic metas-
tases. Today, it is concluded that so-called “Branchiogenic
carcinomas” represent cystic alteration in neck metastasis in
stead of a branchiogeneic carcinoma. Recently, a subgroup
of patients with cystic lymph node masses related to SCC,
that often lack the presence of the classical risk factors for
SCC, has been identiﬁed and related to HPV-associated
SCC [23] .T h ep r e s e n c eo fH P Vc a nb ed e t e c t e di nF N A C
material [24] and directs the search for a primary cancer
arising in the oropharynx. However, cystic masses will often
lead to a negative misleading FNAC ﬁnding, indicating
repeated ultrasound-guided FNAC from solid parts in the
cysts [8, 25]. In general, high sensitivity and speciﬁcity
percentages of 81% and 100%, respectively, are reported
for FNAC allowing the clinician to be conﬁdent of malig-
nancy in a clinically suspicious lesion [26–29], but lower
speciﬁcity percentages (57%) have also been found [30].
Cheng and Dorman [26] conclude that diagnostic accuracy
improveswithexperienceandgoodcommunicationbetween
cytopathologist and clinician. Only repetitive negative or
nondiagnostic FNACs are an indication for an incisional,
excisional, or (image-guided) true-cut biopsy. Although a
direct eﬀect of a neck node biospsy on tumor recurrence
has not been demonstrated [31], we still do not advise to
perform an incisional biopsy because of the adverse eﬀect onInternational Journal of Surgical Oncology 3
subsequent surgery of the neck by scar formation. In case of
a lymphoid proliferation, Fluorescence-Activated Cell Sorter
(FACS) analysis of the aspirate collected in RPMI medium
is helpful in distinguishing reactive lymph nodes from NHL
with monoclonal lymphoid cell proliferation. This method is
less invasive than fresh lymph node biopsies and with similar
result. However, for deﬁnitive NHL classiﬁcation a complete
( f r e s h )l y m p hn o d ee x c i s i o ni sn e e d e d
2.3. FNAC: Squamous Cell Carcinoma. Cytological diagnosis
of SCC and negative routine ENT and skin examination
results, require accurate panendoscopy under general anaes-
thesia of the mucosal lining of the upper aerodigestive
tract. It can be advised to let endoscopy be preceded by
a dedicated imaging process consisting of either MRI (3-
4mmslicethickness)orFDG-PET(/CT)toimprovetheyield
of the procedure [32–35]. Positive predictive values range
from 88% to 62% for FDG-PET and conventional imaging
(CT and-/or MRI), respectively [36]. Early investigations
with FDG-PET have shown equivocal or disappointing
results for the detection of occult primary tumors [37–39].
Ongoing technical improvements in PET image resolution
and sensitivity and integration with CT [40]h a v er e s u l t e d
in better clinical value. In recent publications, FDG-PET was
shown to detect occult primary cancer sites in about 30%
of cases after negative clinical and radiological work-up [41,
42],andincludingpanendoscopy[43].Withimplementation
of the positive predictive value, FDG-PET seems only useful
in approximately 25% of the patients. The optimal place for
FDG-PET in the diagnostic algorithm seems to be prior to
panendoscopy, to avoid false-positive results due to prior
biopsies [41], and to improve the yield of panendoscopy by
guiding biopsy based on the PET results [43]. In addition,
FDG-PET as a wholebody procedure may also improve
staging by demonstrating occult regional and metastatic
disease [39, 41]. In total, adding FDG-PET may induce-
treatment related clinical decisions in up to 60% of cases
[43]. The value of a negative FDG-PET scan has also been
recognised. Most patients with no evidence of a primary
on FDG-PET will never develop a clinically recognisable
primary tumor, especially those who also have negative
ﬁndings on panendoscopy and MRI [42, 44]. False-negative
and false-positive FDG-PET results do occur, especially in
the tonsillar regions, where physiological inﬂammation may
obscure metabolic tumor activity [45]. Therefore, FDG-
PET(/CT) has a place early in the diagnostic algorithm for
detection of an unknown primary in head and neck, but
cannot preclude the need for panendoscopy with biopsy
to detect occult primary tumors [42]. Whilst MRI and/or
PET/CT is the investigation of choice prior to panendoscopy,
CT scanning should be acknowledged as an acceptable
alternative for those clinicians who do not have ready access
to these imaging modalities.
During the process of careful mucosal examination one
should keep in mind that in the Western world the base of
tongue and tonsillar area are the predilection subsites for
harboring an occult superﬁcially growing primary SCC [16],
whereas in Asia it is the nasopharynx. Suspicious ﬁndings on
clinical examination or imaging studies can direct biopsies
for pathological conﬁrmation of a primary carcinoma. In
case of a normal macroscopic appearance of the whole
mucosa,itisrecommendedtodoanadditionaltonsillectomy
[46], since approximately one quarter of primary tumors
a r ed e t e c t e da tt h i ss i t e[ 34, 47–49]. For those patients
with both negative endoscopic and imaging ﬁndings, it
can be questioned whether ipsilateral tonsillectomy and
blinded biopsies from the base of tongue, nasopharynx,
and piriform sinus are to be recommended [42, 44]. It is
not clear from the literature, whether bilateral tonsillectomy
has been established as the standard procedure in cancer
of unknown primary origin [50]. The rate of contralateral
spreadofmetastaticcancerfromocculttonsillesionsappears
toapproach10%[51].Forthisreason,bilateraltonsillectomy
can be recommended without losing time for adequate
treatment.
With the above described algorithmic approach (Figures
2(a) and 2(b)), only 2% of head and neck malignancies will
ﬁnallybeclassiﬁedasoriginatingfromunknownprimarysite
in the head and neck region [1].
The rising incidence of cutaneous SCC worldwide makes
it increasingly likely that clinicians may also encounter
regional nodal metastases of this type of skin cancer in
the parotid gland and the upper levels of the neck [52].
Therefore, high risk areas such as ear and scalp should also
be examined thoroughly. If neck nodes are found in levels Va
and Vb, examination of the skin of the neck and torso should
be performed as well. Although rare, Merkel cell carcinoma
is another cutaneous aggressive malignancy of which half of
the cases presents primarily in the head and neck with a high
propensity for neck node metastases [53].
The absence of an exact location of the primary creates
an enormous dilemma, particularly with respect to whether
all potential primary tumor sites need to be treated with
radiotherapy [34, 47, 54]. In theory, radiation therapy
could be given to the involved ipsilateral neck only, to
candidate primary sites and involved neck, or to the bilateral
neck and potential primary sites. All published studies on
this topic are of retrospective nature. However, some of
these papers suggest that inclusion of extensive radiation
to candidate primary sites and bilateral neck results in less
locoregional failures as compared to ipsilateral neck radia-
tion only [5, 41, 55]. Summarizing theavailableretrospective
literature data, Nieder et al. [34] concluded that patients
receiving nodal resection and bilateral neck irradiation,
including the potential primary mucosal sites, appeared to
have better locoregional control than neck surgery with
ipsilateral radiation or radiotherapy alone. On the other
hand, some retrospective single-institution studies reported
that radiation to the ipsilateral neck only was not associated
withdecreasedsurvivalorhigheremergenceratesofmucosal
primaries [5, 56–58]. A confounding factor in these series
may be the fact that in reported unilateral irradiation to
the neck alone a considerable portion of the (ipsilateral)
mucosal sites might have received radiation due to the use
of nonconformal radiation techniques in the past.
There is no direct comparative data on the use of ipsi-
lateral mucosal irradiation (e.g., to the tonsillar fossa or the4 International Journal of Surgical Oncology
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Figure 2:(a)Algorithmofadiagnosticprocedureforasuspiciouslymphnodeintheneck,emphasizingthepivotalroleof(Ultrasound)Fine
Needle Aspiration Cytology [(US)FNAC]. (b) Algorithm of a diagnostic procedure for a suspicious lymph node in the neck with emphasis
on further steps to be taken after positive FNAC results. EGA: examination under general anaesthesia; LCUC: large cell undiﬀerentiated
carcinoma; MDT: multidisciplinary team; SCC: squamous cell carcinoma; ∗CT scan can serve as an acceptable alternative; ∗∗Excision
indicated if FACS (Fluorescence activated cell sorting by Flow Cytometry) reveals monoclonal lymphoid proliferation.
lateralized base of tongue) versus extensive bilateral mucosal
irradiation with regard to the prevention of occurrence of
primary tumors. However, some of the previously quoted
[5, 56–58] ipsilateral neck radiation series (that will have
included ipsilateral mucosal irradiation too) did not report
increased rates of emergence of primary tumors compared
to extensive radiation.
One obvious concern of extensive radiation is the
development of normal tissue toxicity, including long-term
xerostomia which may signiﬁcantly decrease quality of
life [59]. Modern radiation therapy techniques like IMRT
may overcome some of these issues and result in sparing
(one of) the salivary glands. One should weigh carefully
the diﬀerent treatment modalities like neck surgery alone
[(selective) neck dissection], comprehensive irradiation of
bilateral cervical nodes versus radiation to the ipsilateral
neck along with putative primary sites, nodal excision
or selective neck dissection followed by radiotherapy or
primary chemoradiation with salvage neck dissection in
reserve.International Journal of Surgical Oncology 5
Considering toxicity, a patient-tailored-individualized
treatment approach could be applied consisting of ipsilateral
radiation only in case of favorable neck disease after neck
dissection (e.g., pN1 without extranodal extension). In cases
with bilateral nodal metastases, extensive unilateral involve-
ment with regard to number and levels of nodal metastases,
or extranodal extension, comprehensive radiation should be
considered. Unfortunately, a randomized trial by EORTC
a n dR T O Gt oi n v e s t i g a t ew h e t h e ro rn o tc o m p r e h e n s i v e
radiation to bilateral neck and potential candidate mucosal
sites would lead to improved results compared to ipsilateral
neck radiation only failed due to poor accrual.
2.4. Adenocarcinoma. Adenocarcinoma containing neck
nodes from UPS are exceptional [7], theoretically occurring
in any neck level. If detected in levels I–III, they raise a
high suspicion for a metastasis from a salivary gland carci-
noma, including also the small submucosal salivary glands.
Metastases from a thyroid gland carcinoma are mainly found
in levels II–VI. Metastases located in level IV and VB
(supraclavicular) are exceptional and, if not from thyroid
origin, suspicious for the existence of a primary carcinoma
below the clavicles (lung, mammary gland, prostate, and
gastro intestinal tract).
CT scans of the lungs and abdomen, mammography,
ultrasound of the thyroid, and urological examination,
including determination of PSA serum values in males and
CEAinallpatients,shouldbeusedforclinicalwork-up.PET-
CT scan can replace conventional CT for the identiﬁcation
of the primary tumor with a reported detection rate of 57%
[60]. For neck node metastases in levels I–III, we also advise
a thorough ﬁber endoscopic ENT examination, including
ultrasound of the parotid glands.
In some cases, the cytopathologist can do several
immunohistochemical analyses with the embedded aspirate
to help distinguish diﬀerent adenocarcinomas [61–63].
In the majority of patients presenting with an adenocar-
cinomaintheneck,itistheﬁrstsignofdisseminateddisease.
Nevertheless, in isolated neck nodes a prolonged survival
of median 25 months can be achieved by a selective neck
dissection followed by radiotherapy [19]. See for algorithm
Figures 2(a) and 2(b).
2.5. Large Cell Undiﬀerentiated Carcinoma (LCUC). Isolated
metastases from LCUC may either be derived from an occult
primary SCC of the head and neck or an adenocarcinoma.
Combination of FNAC and immunohistochemistry and
interpretation by an experienced head and neck pathologist
is of utmost importance. For a deﬁnitive distinction between
adenocarcinoma and LCUC recognition of growth patterns
and mucin stains remains a crucial part of the diagnostic
process [64]. In those cases where the ﬁnal cytological
diagnosis of an LCUC remains, algorithmic pathways for the
search of an occult primary of both adenocarcinoma and
SCC should be implemented. The possibility of a primary
salivary gland carcinoma should be taken into account. If
no primary has been found, a LCUC is part of a classical
CUP syndrome, with a very poor prognosis. Nevertheless
also for these cases a selective neck dissection followed by
radiotherapymightleadtogoodpalliationorevenprolonged
survival [19]. See for algorithm Figures 2(a) and 2(b).
2.6. Melanoma. A metastasis in the neck or parotid region
from an unknown primary melanoma is a rare event. Out
of a total of 300 patients with head and neck melanoma 17
(5.7%) presented in this way [20]. The work-up of a patient
with a metastatic melanoma from unknown origin requires
an active participation of the dermatologist in the search
for the primary lesion in the skin of the face and scalp. It
is also advisable to perform routine ENT examination to
search for an occult melanoma of the head and neck mucosa
[65]. Additional imaging seems of limited value in detecting
the primary lesion [7], but can be considered to exclude
disseminated disease, especially in patients presenting with
positive lymph nodes. In a systematic review by Krug
et al. [66] wholebody imaging with FDG-PET(/CT) of
patients with AJCC stage III+ revealed distant metastases
with sensitivity 83% and speciﬁcity 85%, with impact on
treatment in 33%. In patients with no distant metastases,
modiﬁed radical neck dissection is still the mainstay of
treatment. Posterolateral neck dissection, removing levels
II–V, is indicated if the metastasis is located in level V.
This dissection should be extended to the postauricular
and occipital lymph node basins. Postoperative radiotherapy
may improve locoregional control for patients with bad
prognosticsigns,thatis,multiplenodesand/orextracapsular
spread [67]. See for algorithm Figures 2(a) and 2(b).
2.7. Thyroid Carcinoma. Well-diﬀerentiated thyroid carci-
n o m a sa sw e l la sm e d u l l a r ya n du n d i ﬀerentiated thyroid
carcinomas have a very high propensity to spread to the
cervical lymphatics [68–70]. In fact, if the diagnosis of
thyroid carcinoma is conﬁrmed by cytology or open biopsy,
it is no longer considered as metastasis of unknown primary
origin. In general, metastases in levels III, IV, and VI should
raise suspicion of a primary thyroid malignancy. Even in
younger females, and especially in patients with familial
traits (MEN1-2) or previous irradiation to the neck these
thyroid malignancies can occur. Apart from a lump in the
thyroid gland at either palpation or US, the cytology plays
a pivotal role in the diagnosis. Well-diﬀerentiated thyroid
carcinomasoftenhaveaquitecharacteristicappearance.IHC
using antibodies to thyroglobulin, TTF-1, or calcitonin can
give further direction to the diﬀerential diagnosis of this
adenocarcinoma.Incaseofdoubt,serumCEAandcalcitonin
should be obtained to exclude a medullary carcinoma.
Undiﬀerentiated thyroid carcinomas are less easily classiﬁed
cytologically. In these patients, the clinical picture of a
fast growing mass in the thyroid area in elderly patients,
combined with a large cell undiﬀerentiated cytology most
often leads to the diagnosis. Lymph node metastases warrant
selective modiﬁed neck dissections with sparing of internal
jugular vein, accessory nerve, and sternocleidomastoid mus-
cle, followed by ablation of functional thyroid remnants with
radioactive iodine. See for algorithm Figures 2(a) and 2(b).6 International Journal of Surgical Oncology
3. Conclusion
Neck node containing metastasis of carcinoma from
unknown primary origin represents squamous cell carci-
noma in the majority of cases among a wide variety of his-
tologies. An algorithmic approach with careful examination
of the head and neck and a pivotal role for ﬁne needle
aspiration may contribute to a more systematic diagnostic
approach preventing unnecessary steps and allow for site-
speciﬁc therapy.
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